Galderma S.A.-Product Pipeline Review-2015

Products Id :- GMDHC06800CDB
|
Pages: 33
|
February 2015
|
Region: Global
|

Request for Sample Report

Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Galderma S.A.-Product Pipeline Review-2015', provides an overview of the Galderma S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Galderma S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Galderma S.A. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Galderma S.A.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Galderma S.A.'s pipeline products

Reasons To Buy

Evaluate Galderma S.A.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Galderma S.A. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Galderma S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Galderma S.A. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galderma S.A.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Galderma S.A. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Galderma S.A. Snapshot 5

Galderma S.A. Overview 5

Key Information 5

Key Facts 5

Galderma S.A.-Research and Development Overview 6

Key Therapeutic Areas 6

Galderma S.A.-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Combination Treatment Modalities 10

Pipeline Products-Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Galderma S.A.-Pipeline Products Glance 13

Galderma S.A.-Late Stage Pipeline Products 13

Phase III Products/Combination Treatment Modalities 13

Galderma S.A.-Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Galderma S.A.-Early Stage Pipeline Products 16

Discovery Products/Combination Treatment Modalities 16

Galderma S.A.-Unknown Stage Pipeline Products 17

Unknown Products/Combination Treatment Modalities 17

Galderma S.A.-Drug Profiles 18

(adapalene + benzoyl peroxide) 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

trifarotene 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

CD2475/101 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

resiquimod 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Galderma S.A.-Pipeline Analysis 22

Galderma S.A.-Pipeline Products by Target 22

Galderma S.A.-Pipeline Products by Route of Administration 23

Galderma S.A.-Pipeline Products by Molecule Type 24

Galderma S.A.-Pipeline Products by Mechanism of Action 25

Galderma S.A.-Recent Pipeline Updates 26

Galderma S.A.-Dormant Projects 27

Galderma S.A.-Company Statement 28

Galderma S.A.-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Disclaimer 33

List of Tables

Galderma S.A., Key Information 5

Galderma S.A., Key Facts 5

Galderma S.A.-Pipeline by Indication, 2015 7

Galderma S.A.-Pipeline by Stage of Development, 2015 8

Galderma S.A.-Monotherapy Products in Pipeline, 2015 9

Galderma S.A.-Combination Treatment Modalities in Pipeline, 2015 10

Galderma S.A.-Partnered Products in Pipeline, 2015 11

Galderma S.A.-Partnered Products/ Combination Treatment Modalities, 2015 12

Galderma S.A.-Phase III, 2015 13

Galderma S.A.-Phase II, 2015 14

Galderma S.A.-Phase I, 2015 15

Galderma S.A.-Discovery, 2015 16

Galderma S.A.-Unknown, 2015 17

Galderma S.A.-Pipeline by Target, 2015 22

Galderma S.A.-Pipeline by Route of Administration, 2015 23

Galderma S.A.-Pipeline by Molecule Type, 2015 24

Galderma S.A.-Pipeline Products by Mechanism of Action, 2015 25

Galderma S.A.-Recent Pipeline Updates, 2015 26

Galderma S.A.-Dormant Developmental Projects,2015 27

Galderma S.A., Other Locations 29

Galderma S.A., Subsidiaries 30

List of Figures

Galderma S.A.-Pipeline by Top 10 Indication, 2015 7

Galderma S.A.-Pipeline by Stage of Development, 2015 8

Galderma S.A.-Monotherapy Products in Pipeline, 2015 9

Galderma S.A.-Partnered Products in Pipeline, 2015 11

Galderma S.A.-Pipeline by Top 10 Target, 2015 22

Galderma S.A.-Pipeline by Top 10 Route of Administration, 2015 23

Galderma S.A.-Pipeline by Top 10 Molecule Type, 2015 24

Galderma S.A.-Pipeline Products by Top 10 Mechanism of Action, 2015 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Current R&D Portfolio of Galderma S.A.; Galderma S.A. - Key Therapeutics; Galderma S.A. - Pipeline Overview and Promising Molecules; Galderma S.A. - News; Galderma S.A. - Latest Updates; Galderma S.A. - Pipeline; Galderma S.A. - Discontinued/Dormant Projects

Galderma S.A.-Product Pipeline Review-2015

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

Wish to Know more

download

For Further Enquiry

apply for job

Know how We Roll

Engage with Us